Enlivex ( (ENLV) ) has issued an announcement.
Enlivex Therapeutics Ltd. announced positive interim results from the first stage of its Phase II Allocetra™ trial for knee osteoarthritis, showing a 47% reduction in pain and significant improvements in joint function and stiffness after six months. These results, demonstrating durable and persistent efficacy, position Allocetra™ as a promising treatment alternative, with no serious adverse events reported, and the trial is progressing as planned with expectations for further data by the third quarter of 2025.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage company focused on macrophage reprogramming immunotherapy. It is developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages into their homeostatic state to rebalance the immune system and address life-threatening and debilitating conditions.
YTD Price Performance: -3.23%
Average Trading Volume: 113,965
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $26.39M
Learn more about ENLV stock on TipRanks’ Stock Analysis page.